News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Appeal Ruling Forces NICE Rethink on Celgene’s Vidaza for MDS
July 27, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Pharmatimes.com -- Patients in the UK with myelodysplastic syndromes will be celebrating news that the National Institute for Health and Clinical Excellence has been ordered to reassess Celgene’s Vidaza for the National Health Service.
Twitter
LinkedIn
Facebook
Email
Print
Legal
MORE ON THIS TOPIC
Government
Cassidy Names Areas of Improvement for FDA’s Regulatory ‘Black Box’
February 19, 2026
·
3 min read
·
Tristan Manalac
CDC
NIH’s Jay Bhattacharya Steps In as Acting CDC Chief
February 18, 2026
·
1 min read
·
Annalee Armstrong
Legal
Court Rejects Two Moderna Defenses in mRNA Vaccine Patent Row With Arbutus
February 18, 2026
·
2 min read
·
Tristan Manalac
CDC
CDC Left Leaderless Again After Acting Director Departs HHS
February 16, 2026
·
1 min read
·
Tristan Manalac